NRx Pharmaceuticals, Inc. (NRXP), Monday announced that along with HOPE Therapeutics, Inc., the company would align with the U.S. Food and Drug Administration on an initial Pediatric Study Plan for NRX-100 for the treatment of suicidal depression in adolescents aged 9 to 17.
The announcement comes as the company has received FDA's feedback and alignment on the proposed iPSP, which is a requirement for filing a New Drug Application.
The company would also conduct additional neurotoxicity studies in juvenile animals to support safety of intravenous ketamine.
NRx said it is on track to file the NDA for NRX-100 in the fourth quarter of 2024, with an anticipated PDUFA date in the second quarter of 2025.
Currently, NRx Pharma's stock is climbing 2.07 percent, to $2.46 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.